Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Expanding Treatment Options for Bleeds Related to Oral Anticoagulants

December 20, 2017 By Law Offices of Thomas J. Lamb, P.A.

UPDATE:  The FDA announced that it will push back its decision on whether to approve the reversal agent AndexXa to May 4, 2018.  The original review date was set for February 3, 2018, but the FDA wanted to consider additional information it had requested from Portola, the drug's manufacturer. (12/28/17).   Risk of Bleeding … [Read more...]

Filed Under: Unsafe Drugs Tagged With: ACC, American College of Cardiology, andexxa, antidotes, apixaban, bleeding reversal agents, dabigatran, direct oral anticoagulants, DOACs, edoxaban, Eliquis, FDA, major bleeding events, oral anticoagulants side effects, Pradaxa, Praxbind, rivaroxaban, Savaysa, Xarelto

New Anticoagulant BevyxXa Approved by the FDA

June 30, 2017 By Law Offices of Thomas J. Lamb, P.A.

On June 23, 2017, a new anticoagulant drug called BevyxXa (betrixaban) was approved by the FDA for the prevention of venous thromboembolism and pulmonary embolism. This drug acts as a direct Factor Xa inhibitor, similar to the other anticoagulant drugs Eliquis, Savaysa, and Xarelto. Unlike the anticoagulant Pradaxa, which is a direct … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, betrixaban, bevyxxa, black-box drug label warning, bleeding risks, direct xa inhibitors, drug injury, drug injury lawsuits, drug side effects, Eliquis, FDA, NOACs, PE, Pradaxa, Pulmonary Embolism, Savaysa, venous thromboembolism, VTE, Xarelto

Pradaxa And Xarelto May Double The Risk Of Heart Attacks Some Patients

April 18, 2017 By Law Offices of Thomas J. Lamb, P.A.

In March 2017 the British Journal of Clinical Pharmacology published this article, “Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants”, which reports on the first retrospective cohort study to compare the risk of acute myocardial infarction (AMI), or heart … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Heart Attacks, Myocardial Infarctions (MI), Pradaxa, Xarelto

Warfarin vs. Eliquis, Pradaxa, Xarelto, and Savaysa: Which is Better?

November 9, 2016 By Law Offices of Thomas J. Lamb, P.A.

There in an ongoing debate amongst medical professionals concerning the effectiveness and safety of warfarin in comparison to the non–vitamin K antagonist oral anticoagulants (NOACs)--such as Eliquis, Xarelto, Savaysa, and Pradaxa--for patients with atrial fibrillation. According to the Healio Cardiology today article, "Merits of warfarin, newer … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, antidotes, bleeding events, blood thinners, drug injury, drug side effects, Eliquis, Gastrointestinal (GI) Bleeds, hemorrhagic strokes, intracranial hemorrhages, NOACs, Pradaxa, reversal agents, safety warnings, Savaysa, warfarin, Xarelto

No Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet

October 26, 2016 By Law Offices of Thomas J. Lamb, P.A.

In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis (apixaban). Earlier this month the medical journal Chest published this article, “Direct comparison of dabigatran, rivaroxaban, and apixaban for … [Read more...]

Filed Under: Unsafe Drugs Tagged With: bleeding risk, Eliquis, Hemorrhages, Prad, Savaysa, Uncontrollable Bleeding Events, Xarelto

What’s in a Name? Debate on What to Call Novel Oral Anticoagulants

September 30, 2016 By Law Offices of Thomas J. Lamb, P.A.

Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis.  The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate. Here is a list of the possible … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, antidotes, bleeding events, blood thinners, DOAC, drug injury, Eliquis, FDA, Gastrointestinal (GI) Bleeds, hemorrhagic strokes, heparin, increased risks, intracranial hemorrhages, NOAC, ODI, Pradaxa, reversal agents, safety warnings, Savaysa, side effects, SODA, TSOAC, warfarin, Xarelto

Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval

August 24, 2016 By Law Offices of Thomas J. Lamb, P.A.

The following Factor Xa inhibitors, which serve as blood-thinner drugs, are being used by an increasing number of patients for stroke prevention and for treatment of deep vein thrombosis and pulmonary embolism: Eliquis (apixaban) from Pfizer/Bristol-Myers Squibb; Xarelto (rivaroxaban) from Bayer/Johnson & Johnson; and, Savaysa … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Eliquis, Savaysa, Uncontrollable Bleeding Events, Xarelto

New Studies Investigate Long-Term Anticoagulation Use & Bleeding Risk

August 1, 2016 By Law Offices of Thomas J. Lamb, P.A.

According to a Patient-Centered Outcomes Research Institute (PCORI) press release from earlier this month, the PCORI Board of Governors approved $6.5 million for research to compare the potential benefits and harms of popular anticoagulant drugs. The study will include the older anticoagulant, Coumadin (warfarin), as well as the newer "novel … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, bleeding risk, drug injury, Eliquis, Pradaxa, Savaysa, Uncontrollable Bleeding Events, Xarelto

Doctors Are Concerned About Lack Of Savaysa Antidote To Stop Bleeding

July 7, 2016 By Law Offices of Thomas J. Lamb, P.A.

I think it is interesting how this recent Healio – HemOnc Today news reports, “Edoxaban safe, effective for extended prevention of recurrent VTE”, ends by focusing on the continuing lack of any FDA-approve antidote for Savaysa, as well as Eliquis and Xarelto. The growing availability of agents for the reversal of bleeding caused by direct oral … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Eliquis, Savaysa, Uncontrollable Bleeding Events, Xarelto

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.